Blogs

Despite the odds for patients diagnosed with a cancerous brain tumor, OHC is offering these patients a fighting chance with more targeted techniques of delivering radiation and help with side effects. The five-year survival rate for patients with a   (Read More)

Charlene Crank always took good care of her health. Then, about five years ago, she began having problems related to her thyroid and menopause. While working with her primary care doctor to manage these health issues, she paid less attention to other   (Read More)

In 2018, OHC was the region’s first adult cancer group to offer chimeric antigen receptor T-cell therapy (CAR-T) to adults with blood cancers. This was a ground-breaking moment in the history of worldwide cancer care and OHC was at the forefront.   (Read More)

February is Gallbladder and Bile Duct Cancer Awareness Month and OHC is giving patients a fighting chance as the only independent cancer group in Ohio to offer a clinical trial for a new treatment for bile duct cancer. The good news about gallbladder   (Read More)

Every year, Cincinnati magazine issues their Top Docs edition, which lists those doctors voted by other doctors as the top in their field of medicine. OHC once again dominated the three cancer categories. The following OHC doctor are included in the   (Read More)

Screenings save lives. They can find diseases early, before you have symptoms, when they’re easier to treat. At OHC, we know that getting the right screening test at the right time is one of the most important things we can do for our health.   (Read More)

Cancer researchers at OHC are offering new hope for patients with advanced breast cancer that has not responded to current treatment options or is inoperable. Sometimes the cells in a breast have a gene that has been altered, called a mutation. This   (Read More)

On Saturday, January 11, OHC’s team of medical, radiation and gynecologic oncology doctors invited all OHC employees to a special celebration to express their gratitude for the exceptional care and compassion they surround patients and their family   (Read More)

January is Cervical Cancer Awareness Month, and OHC is pleased to share that the primary source of cervical cancer – the HPV virus – has decreased since the introduction of the vaccine, Gardasil. “It’s been almost 15 years since Gardasil was   (Read More)

A new clinical trial available at OHC is evaluating the use of the immunotherapy drug, durvalumab, for patients with inoperable, early stage non-small cell lung cancer (NSCLC). The survival rate for lung cancer depends on which stage the cancer has   (Read More)

This time of year, there are numerous Internet posts and articles about thoughtful gift ideas for patients with cancer. The cancer team at OHC would like to offer another idea that might make the holiday of your loved one or someone you know extra   (Read More)

Cancer has no perks. It isn’t positive, humorous or inspiring. That was going to be a challenge for Diana Bosse because she has always approached everything with a positive outlook and a large dose of humor. Even after receiving a cancer diagnosis,   (Read More)

OHC is at the forefront of the newest, most promising cancer treatments through its nationally recognized cancer clinical trial program. The program evaluates the effectiveness of new treatments and provides cancer patients with access to the new   (Read More)

When an OHC cancer patient meets with their doctor and care team, they are always informed of any clinical trial that may help their condition. The benefit of this standard of care at OHC is twofold: the patient may gain early access to the most   (Read More)

OHC is seeing promising responses to the newest approach in treating advanced stomach cancer. Currently, the five-year survival rate for advanced stomach cancer is 68% – if it is caught and treated at an early stage. If the cancer has spread to   (Read More)